425: Core Scientific-CoreWeave Merger: AI Powerhouse Forms

Core Scientific's Board unanimously recommends an all-stock merger with CoreWeave, citing significant pro forma benefits and a 71% premium for stockholders.

Summary

• Core Scientific's Board of Directors unanimously determined that the proposed all-stock transaction with CoreWeave represents the best available alternative for all Core Scientific stockholders.
• Core Scientific stockholders will receive 0.1235 newly-issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock held.
• The exchange ratio of 0.1235 reflects a ~71% premium to the 10-day VWAP exchange ratio as of June 25, 2025, prior to media reports regarding a transaction.
• The exchange ratio represents an approximately 34% increase from CoreWeave's initial offer.
• Core Scientific stockholders will receive an 8.9% ownership stake in the combined leading AI platform.
• The transaction is expected to close in Q4 2025, subject to approval by a majority of Core Scientific's outstanding common shares.
• The combined company is projected to achieve over $500 million in fully ramped, annual run rate cost savings by the end of 2027E.
• CoreWeave is Core Scientific's main colocation customer, projected to constitute ~95% of Core Scientific's colocation revenue and ~76% of its total projected revenue by 2026E.
• The merger eliminates Core Scientific's standalone execution risk on data center delivery and future leasing, as well as its ~$7.3 billion financing need for capital expenditures.

Sentiment

Score: 9

Explanation: The merger offers a significant premium to Core Scientific shareholders, de-risks their investment by eliminating substantial standalone capital needs and execution risks, and positions them in a high-growth AI infrastructure company. The strategic fit and potential synergies are highly positive.

Positives

• Core Scientific stockholders receive a significant ~71% premium to the 10-day VWAP exchange ratio as of June 25, 2025.
• The exchange ratio increased by approximately 34% from CoreWeave's initial offer due to robust negotiations.
• The transaction eliminates Core Scientific's standalone execution risk related to timely delivery of leased data centers and projected future leasing.
• The merger removes Core Scientific's ~$7.3 billion financing need for capital expenditures over the next eight years.
• Core Scientific stockholders gain an 8.9% ownership in a leading, high-growth AI platform, offering potential for incremental price appreciation via multiple expansion.
• The combined company is expected to achieve over $500 million in fully ramped, annual run rate cost savings by the end of 2027E, including lease overhead elimination.
• The verticalization of operations creates a differentiated large-cap AI infrastructure player with enhanced control over power footprint and design of next-gen builds.
• The combined entity will benefit from greater financial flexibility to pursue infrastructure financing strategies, potentially reducing its overall cost of capital.
• CoreWeave's strong momentum, including recent agreements with OpenAI (up to $6.5B) and Meta ($14.2B), positions the combined company to capture a greater share of the ~$400 billion 2028E AI infrastructure market.

Negatives

• CoreWeave indicated an unwillingness to pursue a fixed value deal (with or without a collar) or include cash in its proposal, limiting options for Core Scientific stockholders.
• The transaction involves dilution for CoreWeave shareholders due to the issuance of new shares.
• Core Scientific's standalone plan faced significant capital expenditure requirements of ~$7.3 billion, with over 75% needed in the first four years, and substantial debt financing risk.

Risks

• The completion of the proposed transaction on anticipated terms or at all, including obtaining regulatory approvals and Core Scientific stockholder approval.
• Unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the combined company.
• The possibility that any of the anticipated benefits of the proposed transaction will not be realized or will not be realized within the expected time period.
• The ability of Core Scientific and CoreWeave to integrate their businesses successfully and to achieve anticipated synergies and value creation.
• Potential litigation relating to the proposed transaction that could be instituted against Core Scientific, CoreWeave, or their respective directors and officers.
• Disruptions from the proposed transaction harming Core Scientific's or CoreWeave's business, including current plans and operations, and diversion of management's time and attention.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Rating agency actions and Core Scientific's and CoreWeave's ability to access shortand long-term debt markets on a timely and affordable basis.
• Legislative, regulatory, and economic developments and actions targeting public companies in the artificial intelligence, power, data center, and crypto mining industries.
• Potential business uncertainty, including the outcome of commercial negotiations and changes to existing business relationships during the pendency of the proposed transaction.
• Restrictions during the pendency of the proposed transaction that may impact Core Scientific's ability to pursue certain business opportunities or strategic transactions.
• Acts of terrorism or outbreak of war, hostilities, civil unrest, attacks against Core Scientific or CoreWeave, and other political or security disturbances.
• Dilution caused by CoreWeave's issuance of additional shares of its securities in connection with the proposed transaction.
• The possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• Impacts of pandemics or other public health crises, including the effects of government responses on people and economies.
• Global or regional changes in the supply and demand for power and other market or economic conditions that impact demand and pricing.
• Changes in technical or operating conditions, including unforeseen technical difficulties.
• Development delays at Core Scientific and/or CoreWeave's data center sites, including any delays in the conversion of such sites from crypto mining facilities to high-performance computing sites.
• Core Scientific's ability to earn digital assets profitably and to attract customers for its high-density colocation capabilities.
• Core Scientific's ability to perform under its existing colocation agreements and maintain its competitive position in its existing operating segments.
• The impact of increases in total network hash rate and Core Scientific's ability to raise additional capital to continue its expansion efforts or other operations.
• Core Scientific's need for significant electric power and the limited availability of power resources.
• The potential failure in Core Scientific's critical systems, facilities, or services the company provides.
• The physical risks and regulatory changes relating to climate change and potential significant changes to the method of validating blockchain transactions.
• Core Scientific's vulnerability to physical security breaches, which could disrupt operations.
• A potential slowdown in market and economic conditions, particularly those impacting high-density computing, the blockchain industry, and the blockchain hosting market.
• Price volatility of digital assets and bitcoin in particular.
• Potential changes in the interpretive positions of the SEC or its staff with respect to digital asset mining firms.
• The likelihood that U.S. federal and state legislatures and regulatory agencies will enact laws and regulations to regulate digital assets and digital asset intermediaries.
• Changing expectations with respect to ESG policies and the effectiveness of Core Scientific's compliance and risk management methods.
• The adequacy of Core Scientific's sources of recovery if the digital assets held by Core Scientific are lost, stolen, or destroyed due to third-party digital asset services.

Future Outlook

The combined Core Scientific and CoreWeave entity is positioned to become a leading large-cap AI infrastructure player, capturing a greater share of the rapidly growing ~$400 billion 2028E AI infrastructure market. The merger is expected to accelerate and de-risk the path to scale for both companies, enhance operational efficiency through significant cost savings, and provide greater financial flexibility for infrastructure financing. CoreWeave anticipates continued strong growth, justifying potential multiple expansion compared to its publicly traded peers.

Management Comments

• The Core Scientific Board of Directors unanimously determined that the proposed transaction with CoreWeave represents the best available alternative for all Core Scientific stockholders and recommends all stockholders vote FOR the transaction.
• CoreWeave indicated it was unwilling to pursue a fixed value deal (with or without a collar) or include cash in its proposal, as such terms would not be acceptable to its Board.
• CoreWeave indicated that the June 27th offer represented its best and final offer and has since reaffirmed publicly on October 7th that its bid is best and final.

Industry Context

This merger signifies a strategic vertical integration within the rapidly expanding AI infrastructure market. By combining Core Scientific's data center assets and power expertise with CoreWeave's specialized AI cloud services and GPU access (including a new Nvidia relationship), the new entity aims to create a comprehensive, end-to-end AI technology stack. This move addresses the intense demand for high-performance computing capacity driven by large language models and AI development, positioning the combined company to compete more effectively against hyperscale cloud providers and other specialized AI compute providers.

Comparison to Industry Standards

• CoreWeave currently trades at a significant discount to publicly traded comparable pureplay and diversified cloud companies despite meaningfully higher growth projections.
• CoreWeave's 2026E projected revenue growth of 129.8% significantly surpasses the consensus median of 12.8% for selected public peers.
• CoreWeave's 2026E projected EBITDA growth of 154.2% is substantially higher than the consensus median of 16.2% for selected public peers.
• The 71% premium to the 10-day VWAP unaffected exchange ratio places this all-stock transaction within the top decile of similar transactions since 2004, indicating a historically outsized premium for Core Scientific stockholders.

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against Core Scientific, CoreWeave, or their respective directors and officers is listed as a risk factor.

Related Party Transactions

• The entire transaction constitutes a related party dealing, as CoreWeave is Core Scientific's main colocation customer, representing the vast majority of its current and projected revenue.

Stakeholder Impact

• Shareholders of Core Scientific: Receive a significant premium and ownership in a high-growth AI company, while eliminating standalone risks.
• Shareholders of CoreWeave: Experience dilution from share issuance but gain vertical integration, cost savings, and de-risked growth path.
• Employees: Potential for integration challenges and synergies, but also opportunities within an expanded, leading AI infrastructure player.
• Customers (CoreWeave's clients): Benefit from enhanced control over data center infrastructure, potentially leading to more optimized and reliable AI compute services.
• Creditors: The combined company's greater financial flexibility and reduced cost of capital may improve creditworthiness compared to Core Scientific standalone.

Next Steps

• A special meeting of Core Scientific stockholders is scheduled for October 30, 2025, to consider and vote upon the merger proposal.
• The transaction is expected to close in Q4 2025, subject to stockholder approval.

Key Dates

Recommendation

The merger offers Core Scientific stockholders a substantial 71% premium to the 10-day VWAP unaffected exchange ratio, providing immediate and significant value. It also eliminates Core Scientific's considerable standalone execution risks and a ~$7.3 billion financing need, transitioning them into an 8.9% ownership stake in a leading, high-growth AI infrastructure player. The strategic verticalization, projected $500M+ annual cost savings, and CoreWeave's strong market position in the expanding AI sector make this a highly attractive proposition for Core Scientific shareholders, warranting a strong buy recommendation to capture the premium and future upside.

Keywords

AI infrastructure, merger, Core Scientific, CoreWeave, colocation, data center, high-performance computing, GPU, blockchain, cryptocurrency, SEC filing, stock transaction